Bhavim Desai, MD
Sleep Medicine · Austin, TXNPI 1871886721
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (32.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 65.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $9,908 and has fallen 67.5% since, to $3,218 in 2025. Among sleep medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $92.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$11K
- Eli Lilly$3K
- Harmony Biosciences LLC$1K
- Inspire Medical Systems, Inc.$321
- Avadel CNS Pharmaceuticals, LLC$154
- Abbott$140
- plus $453 from 8 others
What the payments were for
- Consulting fees$2,25513%
- Speaking & faculty fees$5,40032%
- Travel & lodging$3,63822%
- Food & beverage$5,27131%
- Education$2902%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 68 | $11,113 |
| Eli Lilly | 35 | $3,477 |
| Harmony Biosciences LLC | 52 | $1,196 |
| Inspire Medical Systems, Inc. | 6 | $321 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $154 |
| Abbott | 1 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $101 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Idorsia Pharmaceuticals US Inc | 4 | $77 |
| Merck | 5 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Eisai Inc. | 1 | $22 |
| 3b Medical, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,854 in reported general payments places this provider in the 90th percentile of 112 sleep medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NeuproRotigotine | 12 | $10,468 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $9,686 |
| BelsomraSuvorexant | 17 | $7,662 |
| HorizantGabapentin Enacarbil | 12 | $6,129 |
| Lisdexamfetamine Dimesylate | 23 | $3,575 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 78 | $2,485 |
| Dextroamphetamine Sulfate | 16 | $1,426 |
| Eszopiclone | 18 | $551 |
| Gabapentin | 40 | $510 |
| Amphetamine Sulfate | 12 | $361 |
| Methylphenidate Hcl | 12 | $320 |
| Methadone Hcl | 16 | $285 |
| Zolpidem Tartrate | 30 | $237 |
| Clonazepam | 28 | $171 |
| Trazodone Hcl | 24 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $46 | $9,68613 claims |
| MerckBelsomra | $70 | $7,66217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 sleep medicine providers in Texas.
Other sleep medicine in Austin
- Ashwin GowdaAustin$71K
- John HudsonAustin$16K
- Vani VallabhaneniAustin$3K
- Gerard MeskillSugar Land$1M
- Vikas JainFrisco$673K
- Amit VermaHouston$493K
- Jerald SimmonsHouston$165K
- James AndrySan Antonio$100K
- William BurkesBeaumont$99K
- John DebusDallas$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.